Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q2

4587.TEDINET S100OZ1E
Period2022-01-01 → 2022-06-30
Filed2022-08-10
StandardIFRS
ConsolidatedYes
Data checks17 of 17 passed
Key figures · 65
MetricValuePeriodScopeSource row
Revenue¥5.0bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.6bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Revenue¥9.4bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥2.9bn2021-01-01 → 2021-06-30Cons.Revenue IFRS
Revenue¥1.4bn2021-04-01 → 2021-06-30dCons.Revenue IFRS
Operating income−¥1.6bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income−¥393m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Operating income¥436m2021-01-01 → 2021-06-30Cons.Operating profit loss IFRS
Operating income¥442m2021-04-01 → 2021-06-30dCons.Operating profit loss IFRS
Profit before tax−¥1.5bn2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥361m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Profit before tax¥3.8bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥312m2021-01-01 → 2021-06-30Cons.Profit loss before tax IFRS
Profit before tax¥352m2021-04-01 → 2021-06-30dCons.Profit loss before tax IFRS
Net income (owners)−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥227m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥8m2021-01-01 → 2021-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥213m2021-04-01 → 2021-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income−¥227m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Net income¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥8m2021-01-01 → 2021-06-30Cons.Profit loss IFRS
Net income¥213m2021-04-01 → 2021-06-30dCons.Profit loss IFRS
Total assets¥51.9bnat 2022-06-30Cons.Assets IFRS
Total assets¥27.0bnat 2021-12-31Cons.Assets IFRS
Total assets¥24.8bnat 2021-06-30Cons.Total assets IFRS (5-year summary)
Total assets¥26.1bnat 2020-12-31dCons.Assets IFRS
Total liabilities¥27.2bnat 2022-06-30Cons.Liabilities IFRS
Total liabilities¥1.7bnat 2021-12-31Cons.Liabilities IFRS
Total liabilities¥4.9bnat 2020-12-31dCons.Liabilities IFRS
Net assets / equity¥24.7bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥22.6bnat 2021-06-30Cons.Equity IFRS
Net assets / equity¥21.3bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥24.7bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.4bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥22.6bnat 2021-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥21.3bnat 2020-12-31dCons.Equity attributable to owners of parent IFRS
Cash & equivalents¥6.4bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.8bnat 2021-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥7.1bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥10m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.7bn2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥5.0bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥26.7bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥2.3bn2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥450m2021-01-01 → 2021-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥21.6bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥66m2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥45m2021-01-01 → 2021-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-8.132022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-1.752022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥19.962021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-0.072021-01-01 → 2021-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥1.662021-04-01 → 2021-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-8.132022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-1.752022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.812021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-0.072021-01-01 → 2021-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥1.642021-04-01 → 2021-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio47.7%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio93.8%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio91.3%at 2021-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 9
SegmentItemPeriodValue
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.4bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30¥198m
—segment totalrevenue2022-01-01 → 2022-06-30¥5.0bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥5.0bn
—segment totalsegment profit2022-01-01 → 2022-06-30−¥1.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 668
ItemContextValueUnit
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-4770000JPY
Purchase of intangible assets inv cf IFRSCurrentYTDDuration-58228000JPY
Other inv cf IFRSPrior1YTDDuration－JPY
Other inv cf IFRSCurrentYTDDuration-8724000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-450310000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-26679922000JPY
Proceeds from long term borrowings fin cf IFRSPrior1YTDDuration－JPY
Proceeds from long term borrowings fin cf IFRSCurrentYTDDuration22400000000JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration－JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration-560000000JPY
Payments of borrowing fee fin cf IFRSPrior1YTDDuration－JPY
Payments of borrowing fee fin cf IFRSCurrentYTDDuration-212800000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration－JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-69639000JPY
Proceeds from issuance of shares resulting from exercise of share acquisition rights fin cf IFRSPrior1YTDDuration44940000JPY
Proceeds from issuance of shares resulting from exercise of share acquisition rights fin cf IFRSCurrentYTDDuration－JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YTDDuration-356000JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration-87000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration44583000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration21557472000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration75987000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration-241433000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration4629263000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration-5373721000JPY
Cash and cash equivalents IFRSPrior2YearInstant7149358000JPY
Cash and cash equivalents IFRSPrior1YearInstant11746529000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant11778622000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant6372808000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember1118323000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember3906073000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember5024397000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration5024397000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember1118323000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember3906073000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember5024397000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue IFRSCurrentYTDDuration5024397000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember-1389094000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember197529000JPY
Segment profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember-1191565000JPY
Segment profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Segment profit loss IFRSCurrentYTDDuration-1191565000JPY
Business combination related expenses IFRSCurrentYTDDuration368122000JPY
Operating profit loss IFRSCurrentYTDDuration-1559688000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 17 of 17 passed
balance sheet identityconsolidated 2020-12-31pass
balance sheet identityconsolidated 2021-12-31pass rounding
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass